126 related articles for article (PubMed ID: 38597864)
1. Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.
Januzzi JL; Butler J; Del Prato S; Ezekowitz JA; Ibrahim NE; Lam CSP; Lewis GD; Marwick TH; Perfetti R; Rosenstock J; Solomon SD; Tang WHW; Zannad F
J Am Coll Cardiol; 2024 Jul; 84(2):137-148. PubMed ID: 38597864
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.
Januzzi JL; Butler J; Del Prato S; Ezekowitz JA; Ibrahim NE; Lam CSP; Lewis GD; Marwick TH; Rosenstock J; Tang WHW; Zannad F; Lawson F; Perfetti R; Urbinati A
Am Heart J; 2023 Feb; 256():25-36. PubMed ID: 36372245
[TBL] [Abstract][Full Text] [Related]
3. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
[TBL] [Abstract][Full Text] [Related]
4. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.
Januzzi JL; Del Prato S; Rosenstock J; Butler J; Ezekowitz J; Ibrahim NE; Lam CSP; Marwick T; Wilson Tang WH; Liu Y; Mohebi R; Urbinati A; Zannad F; Perfetti R
Cardiovasc Diabetol; 2024 Feb; 23(1):49. PubMed ID: 38302936
[TBL] [Abstract][Full Text] [Related]
5. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Parker J; Seferovic JP; Wilson P; Mittleman RS; Profy AT; Konstam MA
JAMA; 2020 Oct; 324(15):1522-1531. PubMed ID: 33079154
[TBL] [Abstract][Full Text] [Related]
6. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
[TBL] [Abstract][Full Text] [Related]
7. Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.
Scalzo RL; Moreau KL; Ozemek C; Herlache L; McMillin S; Gilligan S; Huebschmann AG; Bauer TA; Dorosz J; Reusch JE; Regensteiner JG
J Diabetes Complications; 2017 Feb; 31(2):449-455. PubMed ID: 27884660
[TBL] [Abstract][Full Text] [Related]
8. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
Lewis GD; Malhotra R; Hernandez AF; McNulty SE; Smith A; Felker GM; Tang WHW; LaRue SJ; Redfield MM; Semigran MJ; Givertz MM; Van Buren P; Whellan D; Anstrom KJ; Shah MR; Desvigne-Nickens P; Butler J; Braunwald E;
JAMA; 2017 May; 317(19):1958-1966. PubMed ID: 28510680
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study.
Dos Santos MR; Alves MNN; Jordão CP; Pinto CEN; Correa KTS; de Souza FR; da Fonseca GWP; Tomaz Filho J; Costa M; Pereira RMR; Negrão CE; Barretto ACP
Am Heart J; 2021 Sep; 239():1-10. PubMed ID: 33992607
[TBL] [Abstract][Full Text] [Related]
10. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration.
Johnson BF; Nesto RW; Pfeifer MA; Slater WR; Vinik AI; Chyun DA; Law G; Wackers FJ; Young LH
Diabetes Care; 2004 Feb; 27(2):448-54. PubMed ID: 14747227
[TBL] [Abstract][Full Text] [Related]
11. Oxygen uptake kinetics and cardiopulmonary performance in lone atrial fibrillation and the effects of sotalol.
Lok NS; Lau CP
Chest; 1997 Apr; 111(4):934-40. PubMed ID: 9106572
[TBL] [Abstract][Full Text] [Related]
12. Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study.
Núñez J; Palau P; Domínguez E; Mollar A; Núñez E; Ramón JM; Miñana G; Santas E; Fácila L; Górriz JL; Sanchis J; Bayés-Genís A
Clin Cardiol; 2018 Apr; 41(4):476-480. PubMed ID: 29663436
[TBL] [Abstract][Full Text] [Related]
13. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
Borlaug BA; Anstrom KJ; Lewis GD; Shah SJ; Levine JA; Koepp GA; Givertz MM; Felker GM; LeWinter MM; Mann DL; Margulies KB; Smith AL; Tang WHW; Whellan DJ; Chen HH; Davila-Roman VG; McNulty S; Desvigne-Nickens P; Hernandez AF; Braunwald E; Redfield MM;
JAMA; 2018 Nov; 320(17):1764-1773. PubMed ID: 30398602
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
[TBL] [Abstract][Full Text] [Related]
16. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
Chalk C; Benstead TJ; Moore F
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD004572. PubMed ID: 17943821
[TBL] [Abstract][Full Text] [Related]
17. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
[TBL] [Abstract][Full Text] [Related]
18. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation.
Gopal K; Karwi QG; Tabatabaei Dakhili SA; Wagg CS; Zhang L; Sun Q; Saed CT; Panidarapu S; Perfetti R; Ramasamy R; Ussher JR; Lopaschuk GD
Cardiovasc Diabetol; 2023 Mar; 22(1):73. PubMed ID: 36978133
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
[TBL] [Abstract][Full Text] [Related]
20. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
